Hepatitis B Virus Entry into Cells

Cells. 2020 Jun 18;9(6):1486. doi: 10.3390/cells9061486.

Abstract

Hepatitis B virus (HBV), an enveloped partially double-stranded DNA virus, is a widespread human pathogen responsible for more than 250 million chronic infections worldwide. Current therapeutic strategies cannot eradicate HBV due to the persistence of the viral genome in a special DNA structure (covalently closed circular DNA, cccDNA). The identification of sodium taurocholate co-transporting polypeptide (NTCP) as an entry receptor for both HBV and its satellite virus hepatitis delta virus (HDV) has led to great advances in our understanding of the life cycle of HBV, including the early steps of infection in particular. However, the mechanisms of HBV internalization and the host factors involved in this uptake remain unclear. Improvements in our understanding of HBV entry would facilitate the design of new therapeutic approaches targeting this stage and preventing the de novo infection of naïve hepatocytes. In this review, we provide an overview of current knowledge about the process of HBV internalization into cells.

Keywords: Hepatitis B virus; entry pathway; virus–host interaction.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Endocytosis
  • Heparin / analogs & derivatives
  • Heparin / physiology
  • Hepatitis B / physiopathology
  • Hepatitis B / therapy
  • Hepatitis B / virology
  • Hepatitis B virus / genetics
  • Hepatitis B virus / pathogenicity*
  • Hepatitis B virus / physiology*
  • Hepatocytes / physiology
  • Hepatocytes / virology
  • Host Microbial Interactions / physiology
  • Humans
  • Organic Anion Transporters, Sodium-Dependent / physiology
  • Proteoglycans / physiology
  • Receptors, Virus / physiology
  • Symporters / physiology
  • Virus Internalization*

Substances

  • Organic Anion Transporters, Sodium-Dependent
  • Proteoglycans
  • Receptors, Virus
  • Symporters
  • heparin proteoglycan
  • sodium-bile acid cotransporter
  • Heparin